Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynactin subunit 1 (DCTN1) is the largest subunit of the dynactin macromolecular complex, a crucial component for dynein-mediated retrograde transport along microtubules[1][2][3]. The p150-glued isoform forms a flexible arm that mediates binding to microtubules, to the dynein intermediate chain, and to microtubule plus-tip tracking proteins[1][2]. Dynactin, together with cytoplasmic dynein, regulates processes including endoplasmic reticulum-to-Golgi transport, centripetal movement of lysosomes and endosomes, mitotic spindle formation, nuclear positioning, and axonogenesis[2][3]. DCTN1 mutations underlie several neurological diseases, such as amyotrophic lateral sclerosis, Perry syndrome, distal hereditary motor neuronopathy, and frontotemporal dementia[3]. DCTN1 is not currently a mainstream therapeutic target but plays a key role in normal neuronal cell functioning and neurodegeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynactin subunit 1 (DCTN1).